<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AiM</journal-id><journal-title-group><journal-title>Advances in Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3402</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aim.2016.69069</article-id><article-id pub-id-type="publisher-id">AiM-69679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  The Isolation of &lt;i&gt;Vibrio cholera&lt;/i&gt; and Other Enteric Bacteria with Molecular Characterization of &lt;i&gt;Vibrio cholera&lt;/i&gt; during the Outbreak of Baghdad/Iraq in 2015
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sarab</surname><given-names>K. Jameel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mostafa</surname><given-names>A. Shafek</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ali</surname><given-names>M. Abdulmohsen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nadira</surname><given-names>S. Mohamed</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sarmad</surname><given-names>R. Naji</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tuhama</surname><given-names>T. Mohammed</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>AL-Yarmouk Teaching Hospital, Baghdad, Iraq</addr-line></aff><aff id="aff2"><addr-line>Department of Gene Bank, University of AL-Nahrain, Baghdad, Iraq</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2016</year></pub-date><volume>06</volume><issue>09</issue><fpage>699</fpage><lpage>715</lpage><history><date date-type="received"><day>19</day>	<month>June</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>8</month>	<year>August</year>	</date><date date-type="accepted"><day>11</day>	<month>August</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Vibrio
   cholera
  , causing acute watery diarrhea known as cholera disease, affects all ages and both genders. Cholera infection outbreaks in Iraq have been reported for several years. The recent cholera outbreak, emerged throughout 2015, was investigated using bacteriological laboratory tests, singleplex and multiplex PCR technique for the detection of V. cholera from stool samples. Furthermore the toxigenic potential coupled with the antibiotic susceptibility test for cholera and other bacteria were also investigated. The stool samples were collected from 5698 patients admitted to Al-Yarmouk Teaching hospital and health care centers in Baghdad/Al-Karkh, Iraq, from the 1<sup>st</sup> of August to the 30<sup>th</sup> of December 2015. The V. cholera was isolated from 194 cases (3.4% of the cases age between 21 - 50 years). In addition, other enteric infections: Salmonellosis and Shigellosis 7 and 21 respectively, protozoan parasite Giardia lamblia and Entamoeba histolytica 2 and 43 cases respectively were also reported. High percentage of V. cholera infection was detected in October (122 cases, 62.8%), compared with other enteric infections that show high percentage of diarrheal disease in September and November. The results have confirmed that the cholera outbreak was caused by V. cholera O1, biotype El Tor, and serotype Inaba. Seven virulence genes were identified ctxA, toxR, zot, ace, rfbO1, tcpA and ompW. Moreover, the cholera isolated strains were found sensitive to most antibiotic but resistant to nalidixic acid.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;V. cholera&lt;/i&gt;</kwd><kwd> Enteric Bacteria</kwd><kwd> Diarrhea Outbreak</kwd><kwd> Virulence Factor Genes</kwd><kwd> Molecular Identification</kwd><kwd> Antimicrobial Sensitivity Test</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Across the globe, infectious gastroenteritis (IGE) is a cause of global morbidity and mortality [<xref ref-type="bibr" rid="scirp.69679-ref1">1</xref>] . There are different etiologic agents that may cause IGE, including bacteria (Shigella, Campylobacter jejuni, Vibrio cholera O1 and 139 and other pathogenic Vibrios), viruses (rotavirus) and parasites ((protozoa: Giardia lamblia and Entamoeba histolytica) and helminthes) [<xref ref-type="bibr" rid="scirp.69679-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref3">3</xref>] . Diarrhea is the dominant symptom of IGE, it represent more than 30% of hospitalizations morbidity [<xref ref-type="bibr" rid="scirp.69679-ref4">4</xref>] , usually begins as acute watery or as dysentery bloody [<xref ref-type="bibr" rid="scirp.69679-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref6">6</xref>] , then leads to weight loss and may cause dehydration [<xref ref-type="bibr" rid="scirp.69679-ref7">7</xref>] . It’s common in all age groups especially in infants and young children, because their digestive and immune systems are still developing and vulnerable to infection [<xref ref-type="bibr" rid="scirp.69679-ref8">8</xref>] . Enteric infections commonly transmitted through fecal-oral route (food and water contamination) [<xref ref-type="bibr" rid="scirp.69679-ref9">9</xref>] . To reduce this risk of the transmission, a good personal hygiene practice and good food handling practice are required [<xref ref-type="bibr" rid="scirp.69679-ref10">10</xref>] . However, it has been suggested that people who have enteric infections should be excluded from the work in a high risk setting (i.e. workers in health care, residential care and child care, food handlers, young children in child care, etc.) because those people represent a source of IGE even when they are clinically asymptomatic for 24 - 48 hrs and have normal stools test [<xref ref-type="bibr" rid="scirp.69679-ref11">11</xref>] .</p><p>Vibrios are Gram-negative, highly motile curved rods with a single polar flagellum. They tolerate alkaline media that kill most intestinal commensal, but they are sensitive to acid. Numerous free-living vibrios are known, some potentially pathogenic. Until 1992, cholera was caused by only two serotypes, Inaba (AC) and Ogawa (AB), and two biotypes, classical and El Tor, of toxigenic O group 1 V. cholera [<xref ref-type="bibr" rid="scirp.69679-ref12">12</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref14">14</xref>] . The bacterium may be identified by agglutination in O group 1-specific antiserum directed against the lipopolysaccharide component of the cell wall and by the demonstration of their enterotoxigenicity. In 1992, cholera caused by serogroup O139 (synonym “Bengal” the 139 and latest serogroup of V. cholera to be identified) emerged in epidemic proportions in India and Bangladesh. This serovar is identified by 1) absence of agglutination in O group 1 specific antiserum; 2) by agglutination in O group 139 specific antiserum; and 3) by the presence of a capsule [<xref ref-type="bibr" rid="scirp.69679-ref12">12</xref>] .</p><p>The pathogenesis of V. cholera involves infection, reaching and colonizing in the epithelium of the small intestine. Within the intestine, where V. cholera express a variety of extracellular aggressive virulence factors, toxin coregulated pilus (TCP) and cholera toxin (CT) are essential for the colonization of the host and enterotoxicity, respectively [<xref ref-type="bibr" rid="scirp.69679-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref16">16</xref>] . The virulence cascade toxR protein of V. cholera regulates the expression of several virulence factors including TCP that play important roles in the pathogenesis of cholera [<xref ref-type="bibr" rid="scirp.69679-ref17">17</xref>] . There are at least 6 virulence genes in V. cholera. These genes are the regulator factors and they are: toxR, cholera toxin (ctxA), toxin coregulated pilus (tcpA), outer membrane protein (OmpW), accessory cholera toxin (ace), zonulaoccludens toxin (zot) and O1 somatic antigen (rfbO1) which may commonly be found in all V. cholera species [<xref ref-type="bibr" rid="scirp.69679-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref19">19</xref>] . People infected with cholera may suffer from different clinical symptoms including vomiting, fever, hypotension, removes essential body fluids, salts and vital nutrients. They may also suffer from body spasm, paralysis and fainting [<xref ref-type="bibr" rid="scirp.69679-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref21">21</xref>] . Patients with severe dehydration, as a result of diarrhea caused by V. cholera, are recognized and they are either treated with oral rehydration fluid and/or intravenous fluid replacement, while antibiotics are not a necessary part of cholera treatment, because it may contributes to the emergence of resistance [<xref ref-type="bibr" rid="scirp.69679-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref23">23</xref>] . Other researchers confirmed to use different antibiotics like trimethoprim-sulfamethoxazole, tetracycline, azithromycin, erythromycin, and ampicillin, which are very useful to reduce the duration of cholera diarrhea [<xref ref-type="bibr" rid="scirp.69679-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref24">24</xref>] .</p><p>To assist with confirmation of V. cholera; numerous diagnostic laboratory tests are applied [<xref ref-type="bibr" rid="scirp.69679-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref26">26</xref>] including stool culture, biochemical test, specialized microscopy, serological test and these include polyvalent, Ogawa, Inaba antisera testing, and singleplex PCR, conventional coupled PCR or real-time PCR with fluorescence; for detecting different genes encoding to the different V. cholera toxins [<xref ref-type="bibr" rid="scirp.69679-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref27">27</xref>] .</p>Cholera Outbreak in Iraq 2015<p>In the last two decades, the cholera disease in Iraq is represented as an epidemics infection [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] . This has worsened especially after 1991 the first Gulf war when the cholera became endemic in all governorates of Iraq [<xref ref-type="bibr" rid="scirp.69679-ref29">29</xref>] . Between 2007 and 2009, many Iraqi people suffered from the cholera disease [<xref ref-type="bibr" rid="scirp.69679-ref24">24</xref>] . At that time, V. cholera O1 serotype (Inaba) was detected and confirmed for. In 2012, V. cholera O1 serotype (Ogawa) was detected and confirmed for [<xref ref-type="bibr" rid="scirp.69679-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref30">30</xref>] . The climatic factors in Iraq may play a role in V. cholera outbreaks and also in the strength, duration, or appearance of these annual seasonal patterns, especially in countries near the equator which have higher and more constant temperatures and thus may encourage the constant level of cholera outbreaks mostly in the warmer months [<xref ref-type="bibr" rid="scirp.69679-ref31">31</xref>] . Furthermore, most of wastewater treatment in Iraq has not been functioned according to golden roles due to the war. This has caused a huge contamination with V. cholera in freshwater across the country. Between September 23 to November 6, 2015, 2651 cholera cases have been reported and confirmed in Baghdad and in other 14 Iraqi governorates; such as serogroup O1 (Inaba serotype) with a few cases of (Ogawa serotype) which affected different age groups and genders [<xref ref-type="bibr" rid="scirp.69679-ref32">32</xref>] . Accordingly, the WHO recommended the necessity to improve water supplies and the infrastructures as well as to equip electricity and sanitary disposal of feces in addition to the betterment of the physical and social conditions especially in the refugee camps, for the control of V. cholera outbreaks [<xref ref-type="bibr" rid="scirp.69679-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref34">34</xref>] .</p><p>The aim of this study is the isolation and identification of the enteric pathogen, the V. cholera in particular, to determine the main source of the diarrhea with the toxigenic (virulent genes) local isolates of Vibrio cholera from the patients admitted to Al-Yarmouk Teaching hospital and from Medical Sectors (health care centers) and identify the antibiotic susceptibility for Vibrio cholera and other enteric bacterial isolates.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Collection of Stool Specimens</title><p>Suspected cholera stool specimens were collected from patients at Al-Yarmouk Teaching hospital and 38 health care centers, Baghdad/Al-Karkh. In this surveillance system, every patient with diarrhea attending the hospital or the care centersis screened for major enteric pathogens. According to the hospital surveillance records, 82% of the patients report to Al-Yarmouk Teaching hospital and 38 health care centers within 1day after the first episode of acute diarrhea, while 18% have report between 1 and 2 days. For this study, water stool samples were collected aseptically from 5698 patients who had no prior medication, from 1<sup>st</sup> of August to 30<sup>th</sup> of December 2015 and the participants are males and females.</p><p>The stool samples that are collected without transport media were immediately transported to the laboratory within 30 min; while from health care center, Cary-Blair transport medium was used. All samples (except stool swab) were examined microscopically for the presence of red and white blood cells, yeast and parasites to assess colonic inflammatory processes. However, to detect ova and parasites trophozoites and/or cyst like Giardia lamblia, and Entamoeba histolytica, the Lugol iodine solution was used [<xref ref-type="bibr" rid="scirp.69679-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref35">35</xref>] .</p></sec><sec id="s2_2"><title>2.2. Bacterial Culture, Isolation and Identification</title><p>Collected stool specimens were immediately placed into alkaline peptone water (APW; Biomark<sup>TM</sup>, India) at pH 8.5 as an enrichment media for vibrios [<xref ref-type="bibr" rid="scirp.69679-ref36">36</xref>] , and incubated at 37˚C for 6 hrs., then streaked using an inoculating loop onto selective media thiosulfate citrate bile salts sucrose (TCBS), MacConkey agar, and blood agar (Biomark<sup>TM</sup>, India) and incubated at 37˚C for 18 to 24 h [<xref ref-type="bibr" rid="scirp.69679-ref37">37</xref>] .</p><p>Regarding the isolation of Salmonella, the stool samples were inoculated into selective enrichment media tetrathionate broth with Iodine-iodide solution (Ibn Al-betar Research Center, Iraq) and incubated at 37˚C for 18 to 24 hrs., then streaked using an inoculating loop onto selective media, Xylose lysine deoxycholate agar (XLD; Conda, Spain) and Hektoen agar (HK; Biorex, UK) then incubated at 37˚C for 18 to 24 hrs. For Shigella, stool sample have been inoculated directly into the selective media [<xref ref-type="bibr" rid="scirp.69679-ref38">38</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref39">39</xref>] .</p></sec><sec id="s2_3"><title>2.3. Biochemical Tests</title><p>All bacterial isolates Vibrio, Salmonella and Shigella were diagnosed according to their biochemical tests the Oxidase, Indole, kligler Iron agar (KIg)-slant-(sugar ferment-gas-H2S), Urease, Simmon citrate media, API 20 E and API 20 NE (Biomereumix, France). In addition to Cholera Red, String test and Polymyxin B disc were done for Vibrios [<xref ref-type="bibr" rid="scirp.69679-ref15">15</xref>] . All bacterial isolates were sent to the Central Public Health Laboratory (CPHL), Ministry of Health/Baghdad-Iraq to prove it Vibrio cholera, Salmonella and Shigella.</p></sec><sec id="s2_4"><title>2.4. Serogrouping</title><p>V. cholera colonies from KIg; (Biorex, UK) slant were tested to identify their serogroups using slide agglutination with polyvalent anti-Ogawa and anti-Inaba antisera (Denka seiken co. LTP-JAPAN) [<xref ref-type="bibr" rid="scirp.69679-ref40">40</xref>] . V. cholera O1 were preserved at −20˚C in glycerol for subsequent detection of V. cholera by multiplex PCR.</p></sec><sec id="s2_5"><title>2.5. DNA Preparation</title><p>DNA extraction was carried out according to the enrichment by culturing in alkaline peptone water (1% Bacto Peptone, 0.5% NaCl, 0.07% Na<sub>2</sub>CO<sub>3</sub>, 0.01% KNO<sub>2</sub>, pH 8.6) for 24 hrs. at 37˚C. Grown cultures were plated on TCBS agar plates and Kliglar iron slant. All isolates were routinely grown on Luria-Bertani (LB; Oxoid, UK) agar throughout the study. The Wizard&#174; Genomic DNA Purification Kit (Promega, USA) was used according to the manufacturer’s instructions. The V. cholera DNA detection were done using agarose gel electrophoresis which viewed with the red safe DNA stain and UV transilluminator (BioRad, USA).</p></sec><sec id="s2_6"><title>2.6. PCR Assays</title><p>The PCR reaction was in 40 &#181;l of a 5X FIREPol&#174; Master Mix Ready to Load (solisBioDyne). Optimization of multiplex PCR was accomplished after several trials. Amplification was conducted using the following conditions: 1 cycle pre-denaturation at 95˚C for 10 min, 35 cycles of secondary denaturation at 95˚C for 1 min, annealing at 61.5˚C for 1 min, extension at 72˚C for 1.2 min, and final extension at 72˚C for 10 min. The amplified products were separated with 2.5% agarose gel and viewed using transilluminator (BioRad, USA).</p></sec><sec id="s2_7"><title>2.7. Sequencing and Data Analysis</title><p>For the genes (ctxA, tcpA, ace, rfbO1, toxR, ompW and zot) using the cleanup PCR by (microClean,) using genetic analyzer 3100 (Applied Biosystems, USA) data were analyzed using Sequencing Analysis 5.2. The genes sequences submitted to NCBI/Gene bank database with accession numbers KX096224-KX096236, respectively.</p></sec><sec id="s2_8"><title>2.8. Antibiotic Susceptibility Profile of Bacterial Isolates</title><p>All bacterial isolates were subjected to Kirby-Bauer method for susceptibility test, using disk diffusion technique; it was accomplished on Muller-Hinton agar [<xref ref-type="bibr" rid="scirp.69679-ref41">41</xref>] . For V. cholera, the following antibiotics are used: amikacin, ampicillin, cephalothin, cefotaxime, chloramphenicol, gentamicin, erythromycin, nalidixicacid, and tetracycline (Al-Razi Diagnostics Center/Iraq and Bioanalys /Ankara-Turkay). For Salmoella and Shigella the following antibiotics were used amoxicillin/clavulanic acid, tetracycline, ciprofloxicin, cefotaxime, ceftriaxone, azothromycin, aztreonam, co-trimoxazole, amoxicillin, ampicillin, chloramphenicol, imipenem (Al-Razi Diagnostics Center/Iraq and Bioanalys /Ankara-Turkay) [<xref ref-type="bibr" rid="scirp.69679-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref42">42</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref44">44</xref>] .</p></sec><sec id="s2_9"><title>2.9. Statistical Analysis</title><p>Data were submitted to statistical analysis using EpiInfo-6 software program. Tables of frequency and percentage were issued. Chi-square test was calculated to explore the significance of the relationship between different variables, P value ≤ 0.05 was considered as positive level of significance.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Isolates</title><p>From 1<sup>st</sup> of August to 30<sup>th</sup> of December 2015, 5698 stool samples were examined. The result was 194 as V. cholera, 21 as Shigella spp. (mostly Shig. flexneri), and 7 Salmonella spp. (mostly Sal. typhi). All Vibrio cholera isolates belong to the pattern of O1 serogroup, biotype-El-Tor, serotype Inaba. Protozoan parasite Giardia lamblia 2and Entamoeba histolytica 43 were also reported.</p></sec><sec id="s3_2"><title>3.2. Infection Pattern and Seasonality</title><p>It is clear that <xref ref-type="table" rid="table1">Table 1</xref> shows the significant results (P &lt; 0.05) of cholera infection. Two peaks were detected in different months: the first peak in September (57 cases) and increased in October (122 cases), followed by the gradual decline in November (14 cases) with only one case in August, finally, in December, no positive case has been recorded. <xref ref-type="table" rid="table2">Table 2</xref> reveals that there is no-significant result (P &gt; 0.05) of cholera infection and other enteric pathogen between the two genders. From 267 of different pathogens present in the study, <xref ref-type="table" rid="table3">Table 3</xref> clearly shows that the highest percentage of V. cholera infection has occurred during October (122 cases (62.9%) compared with the highest percentage of E. histolytica (28 cases (65.1%) and Shigella infection (7 cases (33.3%) in November. Regarding Salmonella, there were only 3 cases reported (42.8%) during September. Concerning G. lamblia, the results revealed only 2 cases distributed in November and December.</p><p>The results in <xref ref-type="table" rid="table4">Table 4</xref> demonstrate that the cholera infections are distributed for all age groups by both gender (P &gt; 0.05). Moreover, the highest percentage of cholera infections was found in the age group of 21 - 30 y (56</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of positive cholera cases according to month of occurrence and gender</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Variable</th><th align="center" valign="middle" >Positive V. cholera No. (%)</th><th align="center" valign="middle" >Negative V. cholera No. (%)</th><th align="center" valign="middle" >Total No. (%)</th><th align="center" valign="middle" >P-value<sup>*</sup></th></tr></thead><tr><td align="center" valign="middle"  rowspan="6"  >Month<sup>**</sup></td><td align="center" valign="middle" >August</td><td align="center" valign="middle" >1 (0.3)</td><td align="center" valign="middle" >292 (99.7)</td><td align="center" valign="middle" >293 (100)</td><td align="center" valign="middle"  rowspan="6"  >0.000001 df = 3</td></tr><tr><td align="center" valign="middle" >September</td><td align="center" valign="middle" >57 (4.5)</td><td align="center" valign="middle" >1207 (95.5)</td><td align="center" valign="middle" >1264 (100)</td></tr><tr><td align="center" valign="middle" >October</td><td align="center" valign="middle" >122 (4.5)</td><td align="center" valign="middle" >2575 (95.5)</td><td align="center" valign="middle" >2697 (100)</td></tr><tr><td align="center" valign="middle" >November</td><td align="center" valign="middle" >14 (1.4)</td><td align="center" valign="middle" >960 (98.6)</td><td align="center" valign="middle" >974 (100)</td></tr><tr><td align="center" valign="middle" >December<sup>**</sup></td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >470 (100)</td><td align="center" valign="middle" >470 (100)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >194 (3.4)</td><td align="center" valign="middle" >5504 (96.6)</td><td align="center" valign="middle" >5698 (100)</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Gender</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >107 (3.7)</td><td align="center" valign="middle" >2785 (96.3)</td><td align="center" valign="middle" >2892 (100)</td><td align="center" valign="middle"  rowspan="3"  >0.212 df = 1</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >87 (3.1)</td><td align="center" valign="middle" >2719 (96.9)</td><td align="center" valign="middle" >2806 (100)</td></tr><tr><td align="center" valign="middle" >total</td><td align="center" valign="middle" >194 (3.4)</td><td align="center" valign="middle" >5504 (96.6)</td><td align="center" valign="middle" >5698 (100)</td></tr></tbody></table></table-wrap><p><sup>**</sup>December doesn’t included in the statistical analysis because there is no cholera case.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Presence of different pathogens in the study stool sample by gender</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Pathogen</th><th align="center" valign="middle" >Male No. (%)</th><th align="center" valign="middle" >Female No. (%)</th><th align="center" valign="middle" >Total No. (%)</th></tr></thead><tr><td align="center" valign="middle" >V. cholera</td><td align="center" valign="middle" >107 (55.2)</td><td align="center" valign="middle" >87 (44.8)</td><td align="center" valign="middle" >194 (100)</td></tr><tr><td align="center" valign="middle" >Salmonella</td><td align="center" valign="middle" >2 (28.6)</td><td align="center" valign="middle" >5 (71.4)</td><td align="center" valign="middle" >7 (100)</td></tr><tr><td align="center" valign="middle" >Shigella</td><td align="center" valign="middle" >10 (47.6)</td><td align="center" valign="middle" >11 (52.4)</td><td align="center" valign="middle" >21 (100)</td></tr><tr><td align="center" valign="middle" >Entamoeba histolytica</td><td align="center" valign="middle" >22 (51.2)</td><td align="center" valign="middle" >21 (48.8)</td><td align="center" valign="middle" >43 (100)</td></tr><tr><td align="center" valign="middle" >Giardia lamblia</td><td align="center" valign="middle" >1 (50)</td><td align="center" valign="middle" >1 (50)</td><td align="center" valign="middle" >2 (100)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >142 (53.2)</td><td align="center" valign="middle" >125 (46.8)</td><td align="center" valign="middle" >267 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Presence of different pathogens in the study stool sample according to month</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Months</th><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >V. cholera</th><th align="center" valign="middle" >Sal.</th><th align="center" valign="middle" >Shi.</th><th align="center" valign="middle" >E.H</th><th align="center" valign="middle" >G.L.</th><th align="center" valign="middle" >Total</th></tr></thead><tr><td align="center" valign="middle" >August</td><td align="center" valign="middle" >293</td><td align="center" valign="middle" >1 (0.5)</td><td align="center" valign="middle" >2 (28.6)</td><td align="center" valign="middle" >4 (19.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >September</td><td align="center" valign="middle" >1264</td><td align="center" valign="middle" >57 (29.4)</td><td align="center" valign="middle" >3 (42.8)</td><td align="center" valign="middle" >5 (23.8)</td><td align="center" valign="middle" >1 (2.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >66</td></tr><tr><td align="center" valign="middle" >October</td><td align="center" valign="middle" >2697</td><td align="center" valign="middle" >122 (62.9)</td><td align="center" valign="middle" >2 (28.6)</td><td align="center" valign="middle" >4 (19.0)</td><td align="center" valign="middle" >5 (11.6)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >133</td></tr><tr><td align="center" valign="middle" >November</td><td align="center" valign="middle" >974</td><td align="center" valign="middle" >14 (7.2)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (33.3)</td><td align="center" valign="middle" >28 (65.1)</td><td align="center" valign="middle" >1 (50)</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >December</td><td align="center" valign="middle" >470</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1 (4.8)</td><td align="center" valign="middle" >9 (20.9)</td><td align="center" valign="middle" >1 (50)</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >5698</td><td align="center" valign="middle" >194 (100)</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >43 (100)</td><td align="center" valign="middle" >2 (100)</td><td align="center" valign="middle" >267</td></tr></tbody></table></table-wrap><p>Sal. = Salmonella, Shi. = Shigella, E.H. = Entamoeba histolytica, G.L. = Giardia lamblia.</p><p>cases; 28.9%), followed by the age groups of 31 - 40 y (42 cases; 21.7%), and 41 - 50 y (35 cases; 18.0%), while less cholera infections have occurred in the age groups below 10 and over 60 y, 13.7 and 13 cases (3.6% and 6.7%) respectively. In general, for the age groups between 11 - 20 y and 51 - 60 y, the cholera infection has affected all of them equally.</p></sec><sec id="s3_3"><title>3.3. The Distribution of Patients with Cholera According to the Different Sources (Sector/District, Medical Center and Hospital)</title><p>The distribution of cholera infection by gender and sectors/districts is illustrated in <xref ref-type="table" rid="table5">Table 5</xref>. The highest percentages were from Al-Alam sector 74 cases (38.1%) followed by Al-Amil sector 54 cases (27.8%) then Al-Dora sector 38 cases (19.6%), while Al-Karkh and Al-Adel sectors, recorded the convergent results 7.7% and 6.7%, respectively. Furthermore, there is no-significant difference between the cholera infection for gender and the residence in different districts (P &gt; 0.05). Nevertheless, statistically high significant value (P = 0.0001) between 154 positive cases infected with V. cholera (9.9%) were admitted to Al-Yarmouk Teaching hospital, compared with 40 positive cases infected with V. cholera (0.96%) from other medical health care centers (<xref ref-type="table" rid="table6">Table 6</xref>).</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of cholera cases according to age groups and gender</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Age/years</th><th align="center" valign="middle"  colspan="2"  >Positive V. cholera</th><th align="center" valign="middle"  rowspan="3"  >Total positive</th><th align="center" valign="middle"  rowspan="3"  >P-value</th></tr></thead><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >Female</td></tr><tr><td align="center" valign="middle" >(+ve)</td><td align="center" valign="middle" >(+ve)</td></tr><tr><td align="center" valign="middle" >-10</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7</td><td align="center" valign="middle"  rowspan="8"  >0.273 df = 5</td></tr><tr><td align="center" valign="middle" >11 - 20</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >21 - 30</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >31 - 40</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >42</td></tr><tr><td align="center" valign="middle" >41 - 50</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >35</td></tr><tr><td align="center" valign="middle" >51 - 60</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle" >61-</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >194</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution the positive cases of Vibrio cholerae by gender and sectors</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Sector/district</th><th align="center" valign="middle"  colspan="3"  >Positive V. cholera</th><th align="center" valign="middle"  rowspan="2"  >Total Positive</th><th align="center" valign="middle"  rowspan="2"  >P-value<sup>*</sup></th></tr></thead><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle"  colspan="2"  >Female</td></tr><tr><td align="center" valign="middle" >AL-Karkh</td><td align="center" valign="middle"  colspan="2"  >12 (80)</td><td align="center" valign="middle" >3 (20)</td><td align="center" valign="middle" >15 (7.7)</td><td align="center" valign="middle"  rowspan="5"  >0.35 df = 4</td></tr><tr><td align="center" valign="middle" >AL-Adeel</td><td align="center" valign="middle"  colspan="2"  >8 (61.5)</td><td align="center" valign="middle" >5 (38.5)</td><td align="center" valign="middle" >13 (6.7)</td></tr><tr><td align="center" valign="middle" >AL-Amil</td><td align="center" valign="middle"  colspan="2"  >28 (51.9)</td><td align="center" valign="middle" >26 (48.1)</td><td align="center" valign="middle" >54 (27.8)</td></tr><tr><td align="center" valign="middle" >AL-Alam</td><td align="center" valign="middle"  colspan="2"  >40 (54.1)</td><td align="center" valign="middle" >34 (45.9)</td><td align="center" valign="middle" >74 (38.1)</td></tr><tr><td align="center" valign="middle" >AL-Dora</td><td align="center" valign="middle"  colspan="2"  >19 (50)</td><td align="center" valign="middle" >19 (50)</td><td align="center" valign="middle" >38 (19.6)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle"  colspan="2"  >107 (55.2)</td><td align="center" valign="middle" >87 (44.8)</td><td align="center" valign="middle" >194 (100)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Distribution of examination results according to source of the sample</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Source of sample</th><th align="center" valign="middle" >Positive for V. cholera</th><th align="center" valign="middle" >Negative for V. cholera</th><th align="center" valign="middle" >Total</th><th align="center" valign="middle" >P-value<sup>*</sup></th></tr></thead><tr><td align="center" valign="middle" >Medical health care centers</td><td align="center" valign="middle" >40 (0.96)</td><td align="center" valign="middle" >4109 (99.04)</td><td align="center" valign="middle" >4149</td><td align="center" valign="middle"  rowspan="3"  >0.0001 df = 1</td></tr><tr><td align="center" valign="middle" >AL-Yarmouk Teaching Hospital</td><td align="center" valign="middle" >154 (9.9)</td><td align="center" valign="middle" >1395 (90.01)</td><td align="center" valign="middle" >1549</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >194 (3.4)</td><td align="center" valign="middle" >5504 (96.6)</td><td align="center" valign="middle" >5698</td></tr></tbody></table></table-wrap></sec><sec id="s3_4"><title>3.4. Primer Design</title><p>The primer sequence was designed for ompW and zot genes in-silico using primer 3 algorithm and, as a result, good primers have appeared for the detection of these genes (<xref ref-type="table" rid="table7">Table 7</xref>). The primers for ctxA, ace, toxR, rfbO1 and tcpA genes were designed according to Fields, Goal and Rivera references [<xref ref-type="bibr" rid="scirp.69679-ref45">45</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref47">47</xref>] .</p></sec><sec id="s3_5"><title>3.5. Genotyping by PCR</title><p>The isolates 194 V. choerae, in which only 35 isolates were confirmed genetically, have the ompW specific species gene (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The detection of the toxigenic strain of V. cholera that possessed the CTX genetic element</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Primer sets used for PCR assay and the amplicons size</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >NO</th><th align="center" valign="middle"  colspan="2"  >Primer name</th><th align="center" valign="middle" >Primer sequence</th><th align="center" valign="middle" >Amplicons size</th><th align="center" valign="middle" >Reference</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >1</td><td align="center" valign="middle"  rowspan="2"  >omp W</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-TGCCTCGGTAGTACCTAATGA-3’</td><td align="center" valign="middle"  rowspan="2"  >486 bp</td><td align="center" valign="middle"  rowspan="2"  >This study</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-GCACCAGCTTTGTAGGTTGC-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle"  rowspan="2"  >tcpA</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-CGTTGGCGGTCAGTCTTG-3’</td><td align="center" valign="middle"  rowspan="2"  >805 bp</td><td align="center" valign="middle"  rowspan="2"  >Goel et al. 2007</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-CGGGCTTTCTTCTTGTTCG-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >3</td><td align="center" valign="middle"  rowspan="2"  >rfbO1</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-TCTATGTGCTGCGATTGGTG-3’</td><td align="center" valign="middle"  rowspan="2"  >538 bp</td><td align="center" valign="middle"  rowspan="2"  >Goel et al. 2007</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-CCCCGAAAACCTAATGTGG-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >4</td><td align="center" valign="middle"  rowspan="2"  >toxR</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-CCTTCGATCCCCTAAGCAATAC-3’</td><td align="center" valign="middle"  rowspan="2"  >779 bp</td><td align="center" valign="middle"  rowspan="2"  >Rivera et al. 2001</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-AGGGTTAGCAACGATGCGTAAG-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >5</td><td align="center" valign="middle"  rowspan="2"  >ctxA</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-CGGGCAGATTCTAGACCTCCTG-3’</td><td align="center" valign="middle"  rowspan="2"  >564 bp</td><td align="center" valign="middle"  rowspan="2"  >Fields et al.1992</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-CGATGATCTTGGAGCATTCCCAC-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >6</td><td align="center" valign="middle"  rowspan="2"  >ace</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-TTGATGGCTTTACGTGGCTT-3’</td><td align="center" valign="middle"  rowspan="2"  >198 bp</td><td align="center" valign="middle"  rowspan="2"  >Rivera et al. 2001</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-GCGCTTGGTCTAACCCTAAA-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >7</td><td align="center" valign="middle"  rowspan="2"  >zot</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5’-GGTGGCTTTTGACATGCATC-3’</td><td align="center" valign="middle"  rowspan="2"  >575 bp</td><td align="center" valign="middle"  rowspan="2"  >This study</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >5’-CCAAATTGTCTACGAGGCGA-3’</td></tr></tbody></table></table-wrap><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Agarose gel electrophoresis result of uniplex PCR products. Lane M: 100 bp ladder, lanes 1, 2 represent toxR gene PCR products (779 bp), lane 3,4 represent tcpA gene PCR products (805 bp), lane 5, 6 represent ctxA gene PCR products (564 bp), lane 7, 8 represent zot gene PCR products (575 bp), lane 9, 10 represent ompW gene PCR products (486 bp), lanes 11, 12 represent rfbO1 gene PCR products (638 bp), lane 13, 14 ace gene PCR products (198 bp), lanes 15, 16 represent multiplex of five gene (tcp, rfbO1, zot, ompW, ace respectively). Electrophoresis was carried out in 2.5% agarose gel supplied with Red safe DNA dye at (5 V/cm) for 2 hrs</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/12-2270791x7.png"/></fig><p>contains ctxA gene, toxR, zot, ace, rfbO1, tcp and ompW genes using singleplex PCR for each single gene were tested and optimized for several trials till reached to the best reaction condition (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Moreover, PCR analysis (Singleplex and Multiplex) revealed that all randomly 35 isolates tested are positive for ctxA, toxR, ace, rfbO1, tcpA and ompW genes (100%). In comparison, only 31 isolates (88.57%) are positive for zot gene. Noteworthy, the ompW genes is a marker for the identification of V. cholera which was shown to be dominant in all of the investigated isolates.</p></sec><sec id="s3_6"><title>3.6. Antimicrobial Drug Susceptibility</title><p>Disk diffusion testing demonstrated that all isolates of V. cholera O1 were highly sensitive (100%) to ampicillin, cefotaxime + clavulanic acid and cephalothin, followed by chloramphenicol, gentamycin and amikacin (99%) (<xref ref-type="table" rid="table8">Table 8</xref>). Nevertheless, cholera isolates show less sensitivity to tetracycline and erythromycin with the rate sensitivity of 37.6% and 12.4%, respectively, whereas all were resistant to nalidixic acid (100%).</p><p>The 21 isolates of Shigella and 7 isolates of Salmonella were sensitive (100%) to ciprofloxacin, aztreonam, ampicillin, chloramphenicol and imipenem. Moreover, Salmonella alone is (100%) sensitive to tetracycline, ceftriaxone, co-trimoxazole, but it shows less resistance to amoxicillin, amoxicillin + clavulanic acid (28.6%, 14.3%) respectively, in comparison with Shigella which shows high resistance to these two types of antibiotics (85.7%, 76.2%) respectively. In general both types of bacteria demonstrate acceptable degree of sensitivity test to cefotaxime and azithromycin (<xref ref-type="table" rid="table9">Table 9</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Phenotypic results, obtained in this study, led to presumptive identification of the Baghdad/Al-Karkh 194 bacterial isolates as the V. cholera O1 serogroup, biotype El Tor and serotype Inaba. This finding is similar to that reported in Baghdad 2007 cholera outbreak and in Babylon in 2012 and 2014 [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref55">55</xref>] . This new variant of V. cholera was first reported in Bangladesh 2002 [<xref ref-type="bibr" rid="scirp.69679-ref48">48</xref>] . Since then, several studies have given reports on the prevalence of V. cholera variants in several Asian countries [<xref ref-type="bibr" rid="scirp.69679-ref49">49</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref54">54</xref>] . This cholera genotype did not exist prior to this period. These results give indication that Iraq cholera disease represents epidemics spreading from some neighboring countries visitors to holy shrine sites in Iraq [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] . This may be due to inadequate supplies and a shortage of health personnel, among other factors which provide adequate conditions for V. cholera O1, biotype El Tor, serotype Inaba to survive better in the warm environment and crowded areas which give better transmission from human to human by food and water since the El Tor strains have efficiency transmission from host to host when compared with classical cholera strains [<xref ref-type="bibr" rid="scirp.69679-ref56">56</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref57">57</xref>] .</p><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Sensitivity of cholera isolates to the antibiotics in vitro</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Antibiotic disc</th><th align="center" valign="middle"  colspan="3"  >V. cholera isolates (N = 194)</th></tr></thead><tr><td align="center" valign="middle" >Sensitive</td><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >Resistant</td></tr><tr><td align="center" valign="middle" >No. (%)</td><td align="center" valign="middle" >No. (%)</td><td align="center" valign="middle" >No. (%)</td></tr><tr><td align="center" valign="middle" >Amikacin</td><td align="center" valign="middle" >192 (99)</td><td align="center" valign="middle" >1 (0.5)</td><td align="center" valign="middle" >1 (0.5)</td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >194 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Chloramphenicol</td><td align="center" valign="middle" >193 (99.5)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1 (0.5)</td></tr><tr><td align="center" valign="middle" >Cefotaxime + Clavulanic acid</td><td align="center" valign="middle" >194 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Cephalothin</td><td align="center" valign="middle" >194 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Erythromycin</td><td align="center" valign="middle" >24 (12.4)</td><td align="center" valign="middle" >170 (87.6)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Gentamycin</td><td align="center" valign="middle" >193 (99.5)</td><td align="center" valign="middle" >1 (0.5)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Nalidixic acid</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >194 (100)</td></tr><tr><td align="center" valign="middle" >Tetracyclin</td><td align="center" valign="middle" >73 (37.6)</td><td align="center" valign="middle" >121 (62.4)</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>S = sensitive, M = moderate sensitivity, R = Resistant.</p><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> The sensitivity test of Salmonella &amp; Shigella isolates to the antibiotics discs</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Antibiotic disc</th><th align="center" valign="middle"  colspan="3"  >Shigella sp (N = 21)</th><th align="center" valign="middle"  colspan="3"  >Salmonella sp (N = 7)</th></tr></thead><tr><td align="center" valign="middle" >S</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >R</td><td align="center" valign="middle" >S</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Amoxicillin + Clavulanic acid</td><td align="center" valign="middle" >5 (23.8)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >16 (76.2)</td><td align="center" valign="middle" >5 (71.4)</td><td align="center" valign="middle" >1 (14.3)</td><td align="center" valign="middle" >1 (14.3)</td></tr><tr><td align="center" valign="middle" >Tetracyclin</td><td align="center" valign="middle" >18 (85.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >3 (14.3)</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Ciprofloxicin</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >13 (61.9)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >8 (38.1)</td><td align="center" valign="middle" >5 (71.4)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2 (28.6)</td></tr><tr><td align="center" valign="middle" >Ceftriaxone</td><td align="center" valign="middle" >20 (95.2)</td><td align="center" valign="middle" >1 (4.8)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Azithromycin</td><td align="center" valign="middle" >19 (90.5)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2 (9.5)</td><td align="center" valign="middle" >6 (85.7)</td><td align="center" valign="middle" >1 (14.3)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Aztreonam</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Co-Trimoxazole</td><td align="center" valign="middle" >5 (23.8)</td><td align="center" valign="middle" >1 (4.8)</td><td align="center" valign="middle" >15 (71.4)</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Amoxicillin</td><td align="center" valign="middle" >3 (14.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >18 (85.7)</td><td align="center" valign="middle" >3 (42.8)</td><td align="center" valign="middle" >2 (28.6)</td><td align="center" valign="middle" >2 (28.6)</td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Chloramphenicol</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Imipenem</td><td align="center" valign="middle" >21 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>S = sensitive, M = moderate sensitivity, R = Resistant.</p><p>In this context, it is noteworthy that the few studies suggested that most of the Iraqi cholera isolates mostly belong to Ogawa serotype and only few are Inaba serotype [<xref ref-type="bibr" rid="scirp.69679-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref58">58</xref>] . Nevertheless, other studies conducted in Iraq revealed that 58 isolates out of 66 V. cholera belong to the pattern under serum Inaba and only 5 isolates are ogawa and 3 isolates belonging to non-cholera vibrios [<xref ref-type="bibr" rid="scirp.69679-ref59">59</xref>] . However, our results are not in agreement with a study done in Baghdad during the 1999 outbreak of cholera [<xref ref-type="bibr" rid="scirp.69679-ref60">60</xref>] and in Haiti from 2010 to 2011 [<xref ref-type="bibr" rid="scirp.69679-ref61">61</xref>] which showed that Ogawa serotype is the predominant. These results may give observation about V. cholera serotype which may change epidemiologically when compared with the past decade [<xref ref-type="bibr" rid="scirp.69679-ref37">37</xref>] .</p><p>In the current study, the rate of diarrhea is approximately similar in male and female. The analysis of this study revealed significant higher occurrence of V. cholera infection in September and October than the other months. The present results are consistent with other studies [<xref ref-type="bibr" rid="scirp.69679-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref32">32</xref>] . Other studies described two annuals of El Tor cholera peaks; these are a smaller spring outbreak in April before the monsoons rains then a larger outbreak from September to December after the monsoon rains [<xref ref-type="bibr" rid="scirp.69679-ref62">62</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref63">63</xref>] . The primary transmission of cholera to the humans have been enabled by several environmental factors such as temperature, salinity, nutrient concentrations, and the plankton in water, shellfish consumption, and aquatic ecosystems [<xref ref-type="bibr" rid="scirp.69679-ref64">64</xref>] , due to ecological responses to recent climate change [<xref ref-type="bibr" rid="scirp.69679-ref62">62</xref>] , in which current climate condition may enable V. cholera to persist in aquatic ecosystems during winter [<xref ref-type="bibr" rid="scirp.69679-ref31">31</xref>] .</p><p>Other important enteric bacterial pathogens such as Salmonella and Shigella were also isolated in this study during August to October (Salmonella 7 and Shigella 21). Furthermore the current study also shows that E. histolytica and G. lamblia have a higher occurrence during November and December. It is well known that enteric infections, caused by the protozoan and bacteria, exhibit seasonal variation. Enteric bacterial infections rise in the summer and decline in the winter, in contrast to protozoan infection which has shifted towards autumn [<xref ref-type="bibr" rid="scirp.69679-ref65">65</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref66">66</xref>] .</p><p>The incidence of diarrhea infections caused by enteric bacteria and protozoan occurred around the year and for the whole age groups [<xref ref-type="bibr" rid="scirp.69679-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref67">67</xref>] . They are considered as a waterborne and food-borne infection [<xref ref-type="bibr" rid="scirp.69679-ref66">66</xref>] , that increase with the increase of temperature, especially in summer when there is water shortage, higher water consumption, outdoor activities and recreational water use such as camping or swimming, then spread infections person-to-person and may amplify outbreaks of enteric diarrhea disease [<xref ref-type="bibr" rid="scirp.69679-ref68">68</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref70">70</xref>] . These conditions, after 2003 are clearly visible in many parts in Iraq such as poor environmental sanitation, coupled with special events such as flood, famine, and refugee movements with overcrowded camps which may assist to increase enteric diarrhea diseases including cholera [<xref ref-type="bibr" rid="scirp.69679-ref71">71</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref73">73</xref>] .</p><p>In the present study, 267 (4.7 %) enteric pathogens, including cholera and protozoa, were isolated out of 5698 diarrhea cases, while there have been 5431 (95.3%) negative cases. The interpretation of this result is that the pathogen was present in the stool sample but was below the limit of detection of the assay. Furthermore, stool sample represent a complex matrix with multiple pathogenic microbes, and finding a rare entero-pathogen is inherently challenging [<xref ref-type="bibr" rid="scirp.69679-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref74">74</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref75">75</xref>] . Cholera infection was detected for all age groups and in both gender (P &gt; 0.05). The highest percentage was found in adult age groups, while less percentage of cholera infection was found in children and older age groups, and in male (55.2%) than in female (44.8%). These percentages are widely acceptable for the cholera infection outbreak in 2015, which was confirmed that 2651 cases comprising of 1477 (55.7%) males and 1174 (44.3%) females, all age groups were included [<xref ref-type="bibr" rid="scirp.69679-ref32">32</xref>] , and, similar to previous researches, it has been shown that age groups were ranged from 12 - 65 years old [<xref ref-type="bibr" rid="scirp.69679-ref76">76</xref>] , and 54.4% are male and 45.6% are female out of 160 cases of cholera infections [<xref ref-type="bibr" rid="scirp.69679-ref33">33</xref>] . On the other hand, these results are inconsistent with other results that reported cholera infections in age groups &lt; 1 year (16.3%), 1 - 5 years (62.5%) and &gt;5 years (21.3%) [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] . Interestingly, the studies in 1999, 2009 and 2014 reported that cholera usually affect the age group between 1 - 5 years and occasionally in the neonatal period 2 - 30 days [<xref ref-type="bibr" rid="scirp.69679-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref58">58</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref77">77</xref>] . It is worth noting that cholera infection in children is less likely to occur presumably due to protection afforded by secretory antibody in mother’s milk [<xref ref-type="bibr" rid="scirp.69679-ref78">78</xref>] . Nevertheless it has been speculated that if cholera occurs in less than five years age, then it could be due to poor sanitation and educational measures of this age groups [<xref ref-type="bibr" rid="scirp.69679-ref79">79</xref>] . In contrast, older age groups appear to have less cholera infection and this could be related to their acquired immunity gained from repeated exposure of diseases whether symptomatic or asymptomatic infection [<xref ref-type="bibr" rid="scirp.69679-ref80">80</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref81">81</xref>] and furthermore the recurrent infections of cholera are rare as a result of the role of local immune defense in the intestinal mucosa [<xref ref-type="bibr" rid="scirp.69679-ref78">78</xref>] .</p><p>Regarding the distribution of patients with cholera in the west of Baghdad, the highest percentage of cholera was isolated from Al-Alam and Al-Amil sectors and less in Al-Dora, Al-Karkh, and Al-Adel sectors. Similar results were also reported for the above mentioned sectors of Baghdad [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref33">33</xref>] . Cholera transmission is a result of fecal contamination of drinking-water which is closely linked to inadequate environmental management [<xref ref-type="bibr" rid="scirp.69679-ref58">58</xref>] . As a result of that, some sectors in Baghdad suffer from the shortage of municipal drinking water. Therefore, the people living in those sectors dig their own wells without using the adequate methods of water treatment, or they transfer their drinking water via unclean tankers [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] . On other hand, infrastructure destruction as a result of the multiple crises which Iraq has suffered from and events such as floods, famine and wars, displacement of populations to inadequate and overcrowded camps for internally displaced persons or refugees [<xref ref-type="bibr" rid="scirp.69679-ref82">82</xref>] , all have participated to spread cholera in Iraq and it has become an epidemic that threatens other neighboring countries since bacterial pathogens can be transmitted via birds, air, foods, and rivers.</p><p>In the current study, 154 (9.9%) positive cases for cholera infection were admitted to Al-Yarmouk Teaching hospital; and 40 (0.96%) positive cases for cholera infection from the 38 medical health care centers. These samples were collected according to the cholera surveillance system of WHO. The results affirm that surveillance for cholera is a critical component to be controlled. Moreover, detecting and reporting the bacterial strains is important, especially new strains which have the potential to cause new epidemics. Cholera outbreaks must be detected quickly especially in areas that have recently experienced deterioration in water sanitation due to natural disasters, civil strife, or recently established refugee camps. Accordingly, appropriate and rapid responses should be undertaken, such as preparation of preparedness plans, training of healthcare staff and pre-positioning of supplies [<xref ref-type="bibr" rid="scirp.69679-ref83">83</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref85">85</xref>] .</p><p>The PCR analysis revealed that all 35 isolates tested from 194 V. cholera isolates were positive for ace, ctxA, ompW, rfbO1, tcpA and toxR genes (100%), while only 31 isolates (88.57%) were positive for zot gene. Similar results were also reported in 2013, 2015 and 2016 [<xref ref-type="bibr" rid="scirp.69679-ref86">86</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref89">89</xref>] . The presented findings agree with result published in 2007 [<xref ref-type="bibr" rid="scirp.69679-ref90">90</xref>] which revealed that all strains tested in multiplex PCR analysis showed positive for ace, ctxB, hlyA, ompU, ompW, rfbO1, rtx, tcpA, toxR and zot virulence genes. On the other hand, all the isolated 35 Vibrio were positive for the ompW gene. The ompW gene acts as an internal control for V. cholera and could be compatible with the biochemical and serological tests which are used to identify the suspects Vibrio isolate [<xref ref-type="bibr" rid="scirp.69679-ref91">91</xref>] , which plays an important role in the physiology of these bacteria and has an impact on the rapid adaptation of the bacteria to the environment [<xref ref-type="bibr" rid="scirp.69679-ref92">92</xref>] representing a species-specific for V. cholera [<xref ref-type="bibr" rid="scirp.69679-ref86">86</xref>] .</p><p>In general, the present study shows that all tested V. cholera isolates belong to O1 serogroup. The somatic O-antigen biosynthesis gene was positive for O1serogroup (rfbO1), in addition to ctxB, zot, toxR and ompW genes. Furthermore the cholera O1 isolates were positive form accessory cholera toxin (ace) and toxin</p><p>coregulated pilus (tcp). Cholera pathogenesis is a complex process and involves synergism of several genes, although cholera toxin (CT) is supposed to be the most important epidemic marker among various toxins produced by V. cholera [<xref ref-type="bibr" rid="scirp.69679-ref91">91</xref>] . Yet the combination of two target genes including ctxA and rfbO1 can be used for differentiation of toxigenic V. cholerae O1 from non-toxigenic because ctxA gene is mainly responsible for watery diarrhea of toxigenic V. cholera [<xref ref-type="bibr" rid="scirp.69679-ref93">93</xref>] . It was found that both clinical and environmental V. cholera strains carriying ctxA, tcpA, ace and zot genes belonged to El Tor biotype [<xref ref-type="bibr" rid="scirp.69679-ref94">94</xref>] . Therefore, we can conclude that, in the present study, the molecular results are compatible with the bacteriology and serology results which indicated that Baghdad/ Al-Karkh section cholera outbreaks in 2015 was caused by a toxigenic V. cholerae O1 the El Tor-Inaba. Thus, several studies have shown that the patients who suffered from moderate cholera diarrhea, associated with isolated V. cholera, lack the zot gene which is considered acceptable because of the potential function of this gene due to the increase of the permeability of the mucosa in small intestinal by affecting the structure of the intercellular tight junction [<xref ref-type="bibr" rid="scirp.69679-ref95">95</xref>] . On other hand, the non-enterotoxigenic V. cholerae cells that lack ace, zot, and ctx genes do not cause diarrhea in volunteers. Interestingly, the presence of ToxR protein is important for the regulation and function of other virulence genes in pathogenic V. cholera [<xref ref-type="bibr" rid="scirp.69679-ref86">86</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref89">89</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref96">96</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref97">97</xref>] .</p><p>The current study shows that cholera isolates are highly sensitive to ampicillin, cefotaxime + clavulanic acid and cephalothin, chloramphenicol, gentamycin and amikacin (99% - 100%), whilst, they are less sensitive to tetracycline (37.6%) and erythromycin (12.4%) and completely resistant to nalidixic acid (100%). It is interesting to find that the results of this study ware close to the results of other studies reported by several researchers [<xref ref-type="bibr" rid="scirp.69679-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref98">98</xref>] . Yet other researchers reported that cholera is sensitive to ampicillin (49.4%), tetracycline (5%), gentamycin (31.2%), trimetheprim (68.8%), erythromycin (38.7%) and nalidixic acid (69.4%) [<xref ref-type="bibr" rid="scirp.69679-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref58">58</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref99">99</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref100">100</xref>] . The variation in the results attributed to the difference of race, ethnicity, age, travel, and species [<xref ref-type="bibr" rid="scirp.69679-ref43">43</xref>] . Clearly V. cholera was found resistant to a commonly used antibiotics such as tetracycline, erythromycin and sensitive to ceftriaxone, cefixim; such behavior may threat through a higher secondary infection rate and by causing illness of longer duration [<xref ref-type="bibr" rid="scirp.69679-ref33">33</xref>] . In general, it was found that the resistance genes are located on large conjugative elements (SXT constins) that are integrated into prfC on the V. cholera chromosome [<xref ref-type="bibr" rid="scirp.69679-ref100">100</xref>] , and this finding have opened space for more investigations and discussion for studying the integrating conjugative elements as well as the mobile genetic elements that can potentially mediate transfer of antimicrobial drug resistance [<xref ref-type="bibr" rid="scirp.69679-ref61">61</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref101">101</xref>] .</p><p>Regarding Shigella isolates, they were found to be sensitive to ciprofloxacin, aztreonam, ampicillin, chloramphenicol and imipenem, tetracycline, ceftriaxone, cefotaxime and azithromycin and they are relatively resistant to co-trimoxazole, amoxicillin and amoxicillin + clavulanic acid. Similar results were also reported [<xref ref-type="bibr" rid="scirp.69679-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref43">43</xref>] . Overusing antibiotics to treat shigellosis may contribute to make this bacterium more resistant to the antibiotics [<xref ref-type="bibr" rid="scirp.69679-ref102">102</xref>] - [<xref ref-type="bibr" rid="scirp.69679-ref104">104</xref>] . Moreover, Salmonella isolates showed sensitivity to most of the above mentioned antibiotics [<xref ref-type="bibr" rid="scirp.69679-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref105">105</xref>] [<xref ref-type="bibr" rid="scirp.69679-ref106">106</xref>] .</p></sec><sec id="s5"><title>5. Conclusion and Recommendation</title><p>Cholera isolates were identified as Vibrio cholera O1 biotype- El Tor serotype Inaba and these isolates harbored various toxigenic and pathogenic genes (toxR, ctxA, tcpA, ompW, ace, zot, rfbO1) and recorded in the NCBI― as an Iraqi cholera isolates outbreaks in 2015. The study revealed that the highest rate of cholera infection was during September to October with the highest percentage rate among adults aged 21 - 50 years. Beside cholera infection, several enteric pathogens were isolated in September to November.</p><p>The current study emphasizes the importance to provide a safe drinking-water from a plants and water projects that utilize chlorine for disinfection. Also, it is important to encourage the usage of novel technologies in the disinfection of water. Moreover, there should be strict and accurate liquid waste disposal through competent sewage system to prevent direct throwing of (untreated) waste into the river. Application of the novel processing technique like phages biotechnology (phages-virus) has the potential to improve liquid waste treatment.</p><p>Health education plays an important role in the prevention of the disease; better understanding of the disease, identification of mode of transmission, and self-hygiene are the main items in this program.</p><p>Furthermore, emphasizing the importance of the adoption of molecular technologies, namely PCR for rapid, qualitative and quantitative cholera diagnosis to replace the microbiological culture media that are time consuming.</p></sec><sec id="s6"><title>Acknowledgements</title><p>Grateful thanks to Dr. Ali H. Hayawi for his help in implementing the statistical aspects of this study and to the biologist Aseel K. Hamzah for unlimited cooperation and assistance in the preparation of all culture media required to complete this work.</p></sec><sec id="s7"><title>Cite this paper</title><p>Sarab K. Jameel,Mostafa A. Shafek,Ali M. Abdulmohsen,Nadira S. Mohamed,Sarmad R. Naji,Tuhama T. Mohammed, (2016) The Isolation of Vibrio cholera and Other Enteric Bacteria with Molecular Characterization of Vibrio cholera during the Outbreak of Baghdad/Iraq in 2015. Advances in Microbiology,06,699-715. doi: 10.4236/aim.2016.69069</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.69679-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Johnson, H.L., Cousens, S., Perin, J., Scott, S., Lawn, J.E., Rudan, I., Campbell, H., Cibulskis, R., Li, M., Mathers, C. and Black, R.E. (2012) Child Health Epidemiology Reference Group of, WHO and UNICEF; Global, Regional, and National Causes of Child Mortality: An Updated Systematic Analysis for 2010 with Time Trends since 2000. The Lancet, 379, 2151-2161. http://dx.doi.org/10.1016/S0140-6736(12)60560-1</mixed-citation></ref><ref id="scirp.69679-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Stoll, B.J., Glass, R.I., Banu, H., Khan, M.I.H. and Ahmed, M. (1983) Value of Stool Examination in Patients with Diarrhea. British Medical Journal, 286, 2037-2040. http://dx.doi.org/10.1136/bmj.286.6383.2037</mixed-citation></ref><ref id="scirp.69679-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Guerrant, R.L., Van Gilder, T., Steiner, T.S., Thielman, N.M., Slutsker, L., Tauxe, R.V., Hennessy, T., Griffin, P.M., DuPont, H., Sack, R.B., Tarr, P., Neill, M., Nachamkin, I., Reller, L.B., Osterholm, M.T., Bennish, M.L. and Pickering, L.K. (2001) Practice Guidelines for the Management of Infectious Diarrhea. Clinical Infectious Diseases, 32, 331-351.  
http://dx.doi.org/10.1086/318514</mixed-citation></ref><ref id="scirp.69679-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Noaman</surname><given-names> A.A. </given-names></name>,<etal>et al</etal>. (<year>2013</year>)<article-title>Acute and Chronic Diarrhea among Hospitalized Infants Aged (1-12) Months</article-title><source> Diyala Journal of Pure Science</source><volume> 10</volume>,<fpage> 1</fpage>-<lpage>10</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.69679-ref5"><label>5</label><mixed-citation publication-type="book" xlink:type="simple">Keusch, G.T., Fontaine, O., Bhargava, A., Boschi-Pinto, C., Bhutta, Z.A., Gotuzzo, E., Rivera, J., Chow, J., Shahid-Salles, S. and Laxminarayan, R. (2006) Diarrheal Diseases. In: Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A. and Musgrove, P., Eds., Disease Control Priorities in Developing Countries, 2nd Edition, World Bank, Washington, DC, Chapter 19.</mixed-citation></ref><ref id="scirp.69679-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Indian Academy of Pediatrics (2011) Chronic and Persistent Diarrhea in Infants and Young Children: Status Statement. Indian Pediatrics, 48, 37-42. http://dx.doi.org/10.1007/s13312-011-0018-9</mixed-citation></ref><ref id="scirp.69679-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Al-Badri, A.A., Al Ammary, M.A.F, Al-Badawi, G.G. and Al-Azawi, S.A. (2007) Relation between Behavioral Factors, Malnutrition and Persistent Diarrhea in Children under Two Years of Age: A Hospital Study. Journal of the Faculty of Medicine Baghdad, 2249, 22-23.</mixed-citation></ref><ref id="scirp.69679-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abu-Ragheef</surname><given-names> L.F. and Hussein A.K.A. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>Incidence of Seasonal Diarrhea among Children at Child’s Central Hospital</article-title><source> Science Journal Nursing</source><volume> 20</volume>,<fpage> 20</fpage>-<lpage>26</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.69679-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kimura, A.C., Johnson, K., Palumbo, M.S., Hopkins, J., Boase, J.C., Reporter, R., Goldoft, M., Stefonek, K.R., Farrar, J.A., Van Gilder, T.J. and Vugia, D.J. (2004) Multistate Shigellosis Outbreak and Commercially Prepared Food, United States. Emerging Infectious Diseases, 10, 1147-1149. http://dx.doi.org/10.3201/eid1006.030599</mixed-citation></ref><ref id="scirp.69679-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Harker, C. (2001) Pre-Employment Health Assessment for Food Handlers: A Survey of Occupational Physicians in the Food Industry. Occupational Medicine, 5, 332-335. http://dx.doi.org/10.1093/occmed/51.5.332</mixed-citation></ref><ref id="scirp.69679-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Government of Western Australia (2015) Guidelines for Exclusion of People with Enteric Infections and Their Contacts from Work, School and Child-Care Settings. Department of Health, 1-3.</mixed-citation></ref><ref id="scirp.69679-ref12"><label>12</label><mixed-citation publication-type="book" xlink:type="simple">Finkelstein, R.A. (1996) Vibrio cholera O1 and O139, and Other Pathogenic Vibrios. In: Baron, S., Ed., Medical Microbiology, 4th Edition, Chapter 24 (Cholera).</mixed-citation></ref><ref id="scirp.69679-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Qu, M., Xu, J., Ding, Y., Wang, R., Liu, P., Kan, B., Qi, G., Liu, Y. and Gao, S. (2003) Molecular Epidemiology of Vibrio cholera O139 in China: Polymorphism of Ribotypes and CTX Elements. Journal of Clinical Microbiology, 41, 2306-2310. http://dx.doi.org/10.1128/JCM.41.6.2306-2310.2003</mixed-citation></ref><ref id="scirp.69679-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">USAID-United State Academy International Development (2014) Iraq Standard Operating Procedures, SOP: NCL – BE 001, Laboratory Identification of Vibrio Cholera. National Cholera Laboratory IRAQ, 1-31.</mixed-citation></ref><ref id="scirp.69679-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Al-Naddawi, T.H. (2010) Molecular Epidemiology of Vibrio cholera in Iraq during Outbreaks 2007 to 2009. Ph.D. Thesis, College of Science, University of Baghdad, Baghdad.</mixed-citation></ref><ref id="scirp.69679-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Weber, G.G., Kortmann, J., Narberhaus, F. and Klose, K.E. (2014) RNA Thermometer Controls Temperature-Dependent Virulence Factor Expression in Vibrio cholera. Proceedings of the National Academy of Sciences of the United States of America, 111, 14241-14246. http://dx.doi.org/10.1073/pnas.1411570111</mixed-citation></ref><ref id="scirp.69679-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fan, F., Liu, Z., Jabeen, N., Birdwell, L.D., Zhu, J. and Kan, B. (2014) Enhanced Interaction of Vibrio cholerae Virulence Regulators TcpP and ToxR under Oxygen—Limiting Conditions. Infection and Immunity, 82, 1676-1682.  
http://dx.doi.org/10.1128/IAI.01377-13</mixed-citation></ref><ref id="scirp.69679-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Koskela, K.A., Matero, P., Blatny, J.M., Fykse, E.M., Olsen, J.S., Nuotio, L.O. and Nikkari, S. (2009) A Multiplatform Real-Time Polymerase Chain Reaction Detection Assay for Vibrio cholera. Diagnostic Microbiology and Infectious, 65, 339-344. http://dx.doi.org/10.1016/j.diagmicrobio.2009.07.009</mixed-citation></ref><ref id="scirp.69679-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Waturangi, D.E. and Fransiscal, M. (2009) Rapid Detection of Virulence Genes in Vibrio cholerafrom Edible Ice in Jakarta. Microbiology Indonesia, 3, 133-138. http://dx.doi.org/10.5454/mi.3.3.7</mixed-citation></ref><ref id="scirp.69679-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Shrestha, S.D., Malla, S., Adhikari, B.R., Shakya, G., Basnyat, S.R. and Sharma, S. (2010) Antibiotic Susceptibility Patterns of Vibrio cholera Isolates. Journal of the Nepal Medical Association, 49, 232-236.</mixed-citation></ref><ref id="scirp.69679-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Jones, T.F. (2012) How Useful Are Stool Studies for Acute Gastroenteritis? Journal of Infectious Diseases, 205, 1334-1335. http://dx.doi.org/10.1093/infdis/jis215</mixed-citation></ref><ref id="scirp.69679-ref22"><label>22</label><mixed-citation publication-type="book" xlink:type="simple">Symington, V. (2011) Death by Diarrhea. In: Burdass, D., Ed., Cholera, Society for General Microbiology, 1-11.</mixed-citation></ref><ref id="scirp.69679-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">WHO (World Health Organization) (2014) Use of Antibiotics for Cholera. Last update—5 March</mixed-citation></ref><ref id="scirp.69679-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Saleh, T.H., Sabbah, M.A., Jasem, K.A. and Hammad, Z.N. (2011) Identification of Virulence Factors in Vibrio cholera Isolated from Iraq during the 2007-2009 Outbreak. Canadian Journal of Microbiology, 57, 1024-1031.  
http://dx.doi.org/10.1139/w11-094</mixed-citation></ref><ref id="scirp.69679-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Keddy, H.K., Sooka, A., Parsons, M.B., Lafourcade, B.M.N., Fitchet, K. and Smith, A.M. (2013) Diagnosis of Vibrio cholera O1 Infection in Africa. Journal of Infectious Diseases, 208, S23-S31. http://dx.doi.org/10.1093/infdis/jit196</mixed-citation></ref><ref id="scirp.69679-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Buss, S.N., Leber, A., Chapin, K., Fey, P.D., Bankowski, M.J., Jones, M.K., Rogatcheva, M., Kanack, K.J. and Bourzac, K.M. (2015) Multicenter Evaluation of the BioFire Film Array Gastrointestinal Panel for Etiologic Diagnosis of Infectious Gastroenteritis. Journal of Clinical Microbiology, 53, 915-925. http://dx.doi.org/10.1128/JCM.02674-14</mixed-citation></ref><ref id="scirp.69679-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Keasler, S.P. and Hall, R.H. (1993) Detecting and Biotyping Vibrio cholera O1 with Multiplex Polymerase Chain Reaction. Lancet, 341, 1661. http://dx.doi.org/10.1016/0140-6736(93)90792-F</mixed-citation></ref><ref id="scirp.69679-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Khwaif, J.M., Hayyawi, A.H. and Yousif, T.I. (2010) Cholera Outbreak in Baghdad in 2007: An Epidemiological Study. Eastern Mediterranean Health Journal, 16, 460-465.</mixed-citation></ref><ref id="scirp.69679-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">WHO (World Health Organization) (2003) Communicable Disease Profile of Iraq.</mixed-citation></ref><ref id="scirp.69679-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">WHO (World Health Organization) (2012) Cholera in Iraq 2012.</mixed-citation></ref><ref id="scirp.69679-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Emch, M., Feldacker, C., Islam, M.S. and Ali, M. (2008) Seasonality of Cholera from 1974 to 2005: A Review of Global Patterns. International Journal of Health Geographics, 7, 31. http://dx.doi.org/10.1186/1476-072X-7-31</mixed-citation></ref><ref id="scirp.69679-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Al-Abbasi, A.R.M. and Aema, S.M. (2015) THE Cholera Epidemic in Iraq during 2015. Tofiq Journal of Medical Sciences, 2, 27-41. http://tjms.tofiq.org/tjms/article/view/48</mixed-citation></ref><ref id="scirp.69679-ref33"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saeed</surname><given-names> B.H.M. </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>A Study of Vibrio cholera Infection in Children</article-title><source> Iraqi Journal of Community Medicine</source><volume> 21</volume>,<fpage> 18</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.69679-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Paddock, C. (2014) Iraq Prepares for Cholera, Diarrheal Disease Outbreaks. 
http://www.medicalnewstoday.com/articles/279058.php</mixed-citation></ref><ref id="scirp.69679-ref35"><label>35</label><mixed-citation publication-type="book" xlink:type="simple">Jawetz, J.B., Melnick, J.L. and Adelbergg’s, E.A. (2016) Vibrio, Campylobacters, Helicobacter and Associated Bacteria. In: Carroll, K.C., Brook, G.A., Miller, S., Morse, S.A., Mietzner, T.A., Detrick, B., Mitchell, T.G., McKerrow, J.H. and Sakanari, J.A., Eds., Jawetz, Melnick, &amp; Adelberg’s Medical Microbiology, 27th Edition, Section III Bacteriology, Chapter 17, McGraw-Hill Education, New York, 253-256.</mixed-citation></ref><ref id="scirp.69679-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Auda, I.G. and Al-kadmy, I.M. (2014) Toxigenic Potential of Vibrio cholera O1 and O139 Serotypes Isolated from Cases of Diarrhea in Baghdad Hospitals. Journal of Biotechnology Research Center, 8, 84-89.</mixed-citation></ref><ref id="scirp.69679-ref37"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alaouadi</surname><given-names> R.F. </given-names></name>,<etal>et al</etal>. (<year>2014</year>)<article-title>Frequency of V. cholera in Babylon Province</article-title><source> Journal of Babylon University/Pure and Applied Sciences</source><volume> 22</volume>,<fpage> 2579</fpage>-<lpage>2590</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.69679-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">WHO (World Health Organization) (2003) Global Salm-Surv. A Global Salmonella Surveillance and Laboratory Support Project of the WHO. Laboratory Protocols Level 1 Training Course: Isolation of Salmonella. Edited by Hendriksen, R.S. (DFVF), 4th Edition, 1-19.</mixed-citation></ref><ref id="scirp.69679-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Mikoleit, M.L. (2010) WHO Global Foodborne Infections Network. “A WHO Network Building Capacity to Detect, Control and Prevent Foodborne and Other Enteric Infections from Farm to Table” Laboratory Protocol: “Isolation of Salmonella and Shigella from Faecal Specimens”. Enteric Diseases Laboratory Branch Centers for Disease Control and Prevention, Atlanta.</mixed-citation></ref><ref id="scirp.69679-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Acharya, T. (2013) Vibrio Cholera Laboratory Diagnosis and Confirmation. Online Medical Microbiology Guide for Student. Laboratory Diagnosis of Bacterial Disease.</mixed-citation></ref><ref id="scirp.69679-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Samanta, P., Ghosh, P., Chowdhury, G., Ramamurthy, T. and Mukhopadhyay, A.K. (2015) Sensitivity to Polymyxin B in El Tor Vibrio cholera O1 Strain, Kolkata, India. Emerging Infectious Diseases, 21, 2100-2102. 
http://dx.doi.org/10.3201/eid2111.150762</mixed-citation></ref><ref id="scirp.69679-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Sirinavin, S. and Garner, P. (2000) Antibiotics for Treating Salmonella Gut Infections. The Cochrane Database of Systematic Reviews, 2, Article ID: CD001167. http://www.ncbi.nlm.nih.gov/pubmed/10796610</mixed-citation></ref><ref id="scirp.69679-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Shiferaw, B., Solghan, S., Palmer, A., Joyce, K., Barzilay, E.J., Krueger, A. and Cieslak, P. (2012) Antimicrobial Susceptibility Patterns of Shigella Isolates in Foodborne Diseases Active Surveillance Network (FoodNet) Sites, 2000-2010. Clinical Infectious Diseases, 54, S458-S463. http://dx.doi.org/10.1093/cid/cis230</mixed-citation></ref><ref id="scirp.69679-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Klochko, A., Bronze, M.S., Wallace, M.R., Talavera, F., Brusch, J.L. and Nettleman, M.D. (2015) Salmonellosis Treatment and Management (Medical Care). http://emedicine.medscape.com/article/228174-treatment</mixed-citation></ref><ref id="scirp.69679-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Fields, P.I., Popovic, T., Wachsmuth, K. and Olsvik, O. (1992) Use of Polymerase Chain Reaction for Detection of Toxigenic Vibrio cholera O1 Strains from the Latin American Cholera Epidemic. Journal of Clinical Microbiology, 30, 2118-2121.</mixed-citation></ref><ref id="scirp.69679-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Rivera, I.N.G., Chun, J., Huq, A., Sack, R.B. and Colwell, R.R. (2001) Genotype Associated with Virulence in Environmental Isolates of Vibrio cholera. Applied and Environmental Microbiology, 67, 2421-2429. 
http://dx.doi.org/10.1128/AEM.67.6.2421-2429.2001</mixed-citation></ref><ref id="scirp.69679-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Goel, A.K., Ponmariappan, S., Kamboj, D.V. and Singh, L. (2007) Single Multiplex Polymerase Chain Reaction for Environmental Surveillance of Toxigenic-Pathogenic O1 and Non-O1 Vibrio cholera. Folia Microbiologica (Praha), 52, 81-85. http://dx.doi.org/10.1007/BF02932143</mixed-citation></ref><ref id="scirp.69679-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Nair, G.B., Faruque, S.M., Bhuiyan, N.A., Kamruzzaman, M., Siddique, A.K. and Sack, D.A. (2002) New Variants of Vibrio cholera O1 Biotype El Tor with Attributes of the Classical Biotype from Hospitalized Patients with Acute Diarrhea in Bangladesh. Journal of Clinical Microbiology, 40, 3296-3299.  
http://dx.doi.org/10.1128/JCM.40.9.3296-3299.2002</mixed-citation></ref><ref id="scirp.69679-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Keramat, F., Hashemi, S.H., Mamani, M., Ranjbar, M. and Erfani, H. (2008) Survey of Antibiogram Tests in Cholera Patients in the 2005 Epidemic in Hamadan, Islamic Republic of Iran. Eastern Mediterranean Health Journal, 14, 768-775.</mixed-citation></ref><ref id="scirp.69679-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Jabeen, K., Zafar, A. and Hasan, R. (2008) Increased Isolation of Vibrio cholera O1 Serotype Inaba over Serotype Ogawa in Pakistan. Eastern Mediterranean Health Journal, 14, 564-570.</mixed-citation></ref><ref id="scirp.69679-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Taneja, N., Mishra, A., Sangar, G., Singh, G. and Sharma M. (2009) Outbreaks Caused by New Variants of Vibrio cholera O1 El Tor, India. Emerging Infectious Diseases, 15, 352-354. http://dx.doi.org/10.3201/eid1502.080943</mixed-citation></ref><ref id="scirp.69679-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Okada, K., Chantaroj, S., Roobthaisong, A., Hamada, S. and Sawanpanyalert, P. (2010) A Cholera Outbreak of the Vibrio cholera O1 El Tor Variant Carrying Classical ctxB in Northeastern Thailand in 2007. The American Journal of Tropical Medicine and Hygiene, 82, 875-878. http://dx.doi.org/10.4269/ajtmh.2010.09-0537</mixed-citation></ref><ref id="scirp.69679-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Teh, C.S.J., Suhaili, Z., Lim, K.T., Khamaruddin, M.A., Yahya, F., Sajili, M.H., Yeo, C.C. and Thong, K.L. (2012) Outbreak-Associated Vibrio cholera Genotypes with Identical Pulsotypes, Malaysia, 2009. Emerging Infectious Diseases, 18, 1177-1179. http://dx.doi.org/10.3201/eid1807.111656</mixed-citation></ref><ref id="scirp.69679-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Mzee, S., Chowdhury, N., Awasthi, S.P., Asakura, M., Hinenoya, A., Iijima, Y. and Shinji Yamasaki, S. (2014) Prevalence of Vibrio cholera O1 El Tor Variant in a Cholera-Endemic Zone of Kenya. Journal of Medical Microbiology, 63, 415-420. http://dx.doi.org/10.1099/jmm.0.068999-0</mixed-citation></ref><ref id="scirp.69679-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Hasson, S.O., Al-Khafagi, Z.A. and Hendi, N.K. (2012) Study of Vibrio cholera with Its Virulence Factors Isolated from Diarrheal Patients in Babylon Province. Medical Journal of Babylon, 9, 152-158.</mixed-citation></ref><ref id="scirp.69679-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Nesper, J., Lauriano, C.M., Klose, K.E., Kapfhammer, D., Kraiss, A. and Reidl, J. (2001) Characterization of Vibrio cholera O1 El Tor galU and galE Mutants: Influence on Lipopolysaccharide Structure, Colonization, and Biofilm Formation. Infection and Immunity, 69, 435-445. http://dx.doi.org/10.1128/IAI.69.1.435-445.2001</mixed-citation></ref><ref id="scirp.69679-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Dougan, G., Huett, A. and Clare, S. (2002) Vaccines against Human Enteric Bacterial Pathogens. British Medical Pulletin, 62, 113-123. http://dx.doi.org/10.1093/bmb/62.1.113</mixed-citation></ref><ref id="scirp.69679-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Al-Naddawi, M.N. and Khalid, Z.H. (2009) A Clinical Study of Vibriosis during 1999 in Al-Mansour Childrens’ Teaching Hospital. The Iraq Postgraduate Medical Journal, 8, 148-152.</mixed-citation></ref><ref id="scirp.69679-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Kadhim, S.A. and Saleh, D.S. (2010) Detection of Some Bacterial Causes of Watery Diarrhea in the Province of Baghdad and Some Northern Governorates with a Study of Pathological Effects. Iraqi Journal of Science, 53, 536-543.</mixed-citation></ref><ref id="scirp.69679-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Al-Abbassi, A.M., Ahmed, S. and Al-hadithi, T. (2005) Cholera Epidemic in Baghdad during 1999: Clinical and Bacteriological Profile of Hospitalized Cases. Eastern Mediterranean Health Journal, 11, 6-13.</mixed-citation></ref><ref id="scirp.69679-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Talkington, D., Bopp, C., Tarr, C., Parsons, M.B., Dahourou, G., Freeman, M., Joyce, K., Turnsek, M., Garrett, N., Humphrys, M., Gomez, G., Stroika, S., Boncy, J., Ochieng, B., Oundo, J., Klena, J., Smith, A., Keddy, K. and Smidt, P.G. (2011) Characterization of Toxigenic Vibrio cholera from Haiti, 2010-2011. Emerging Infectious Diseases, 17, 2122-2129. http://dx.doi.org/10.3201/eid1711.110805</mixed-citation></ref><ref id="scirp.69679-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Lipp, E.K., Huq, A. and Colwell, R.R. (2002) Effects of Global Climate on Infectious Disease: The Cholera Model. Clinical Microbiology Reviews, 15, 757-770. http://dx.doi.org/10.1128/CMR.15.4.757-770.2002</mixed-citation></ref><ref id="scirp.69679-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Sack, R.B., Siddique, A.K., Longini, I.M., Nizam, A., Yunus, M.D., Islam, M.S., Morris, J.G., Ali, A., Huq, A., Nair, G.B., Qadri, F., Faruque, S.M., Sack, D.A. and Colwell, R.R. (2003) A 4-Year Study of the Epidemiology of Vibrio cholerain Four Rural Areas of Bangladesh. Journal of Infectious Diseases, 187, 96-101.  
http://dx.doi.org/10.1086/345865</mixed-citation></ref><ref id="scirp.69679-ref64"><label>64</label><mixed-citation publication-type="book" xlink:type="simple">Colwell, R.R. and Spira, W.M. (1993) The Ecology of Vibrio cholera. In: Barua, D. and Greenough, W.B., Eds., Cholera: Current Topics in Infections Disease, 3rd Edition, Plenum Medical Book Co., New York, 3-60.</mixed-citation></ref><ref id="scirp.69679-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Bowman, C., Flint, J. and Pollari, F. (2003) Canadian Integrated Surveillance Report: Salmonella, Campylobacter, Pathogenic E. coli and Shigella, from 1996 to 1999. Canadian Communicable Disease Report, 29, 1-6.</mixed-citation></ref><ref id="scirp.69679-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Naumova, E.N., Jagai, J.S., Matyas, B., Demaria, A.J.R., Macneill, I.B. and Griffiths, J.K. (2007) Seasonality in Six Enterically Transmitted Diseases and Ambient Temperature. Epidemiology and Infection, 135, 281-292. 
http://dx.doi.org/10.1017/S0950268806006698</mixed-citation></ref><ref id="scirp.69679-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Khudair, M.K., Jawad, S.J. and Nazal, M.F. (2011) Study the Causes of Parasitic Diarrhea in Children in Al-Ahded Village, Dyalagovernarate. Baghdad for Sciences Journal, 8, 887-890.</mixed-citation></ref><ref id="scirp.69679-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Fleming, C.A., Caron, D., Gunn, J.E., Horine, M.S., Matyas, B.T. and Barry, M.A. (2000) An Outbreak of Shigella sonnei Associated with a Recreational Spray Fountain. American Journal of Public Health, 90, 1641-1642. 
http://dx.doi.org/10.2105/AJPH.90.10.1641</mixed-citation></ref><ref id="scirp.69679-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.H., Levy, D.A., Craun, G.F., Beach, M.J. and Calderon, R.L. (2002) Surveillance for waterborne-Disease Outbreaks—United States, 1999-2000. CDC/MMWR, Surveillance Summaries, 51, 1-28.  
http://mmwrq@cdc.gov</mixed-citation></ref><ref id="scirp.69679-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Stuart, J.M., Orr, H.J., Warburton, F.G., Jeyakanth, S., Pugh, C., Morris, I., Sarangi, J. and Nichols, G. (2003) Risk Factors for Sporadic Giardiasis: A Case-Control Study in Southwestern England. Emerging Infectious Disease, 9, 229-233. http://dx.doi.org/10.3201/eid0902.010488</mixed-citation></ref><ref id="scirp.69679-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">Gardner, T.B. and Hill, D.R. (2001) Treatment of Giardiasis. Clinical Microbiology Reviews, 14, 114-128. 
http://dx.doi.org/10.1128/CMR.14.1.114-128.2001</mixed-citation></ref><ref id="scirp.69679-ref72"><label>72</label><mixed-citation publication-type="other" xlink:type="simple">Calzada, F., Cervantes-Martínez, J.A. and Yépez-Mulia, L. (2005) In Vitro Antiprotozoal Activity from the Roots of Geranium mexicanumand Its Constituents on Entamoeba histolytica and Giardia lamblia. Journal of Ethnopharmacology, 98, 191-193. http://dx.doi.org/10.1016/j.jep.2005.01.019</mixed-citation></ref><ref id="scirp.69679-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">WHO (World Health Organization) (2015) Cholera-Iraq. Disease Outbreak News 12 October.  
http://www.who.int/csr/don/12-october-2015-cholera/en/</mixed-citation></ref><ref id="scirp.69679-ref74"><label>74</label><mixed-citation publication-type="other" xlink:type="simple">Guarino, A. and Giannattasio, A. (2011) New Molecular Approaches in the Diagnosis of Acute Diarrhea: Advantages for Clinicians and Researchers. Current Opinion Gastroenterology, 27, 24-29. 
http://dx.doi.org/10.1097/MOG.0b013e3283413750</mixed-citation></ref><ref id="scirp.69679-ref75"><label>75</label><mixed-citation publication-type="other" xlink:type="simple">Operario, D.J. and Houpt, E. (2011) Defining the Etiology of Diarrhea: Novel Approaches. Current Opinion Infectious Diseases, 24, 464-471. http://dx.doi.org/10.1097/QCO.0b013e32834aa13a</mixed-citation></ref><ref id="scirp.69679-ref76"><label>76</label><mixed-citation publication-type="other" xlink:type="simple">Al-Shok, M.M. and Baey, H.A. (2009) Clinical Study on Cholera Patients in Babylon. Medical Journal of Babylon, 6, 420-423.</mixed-citation></ref><ref id="scirp.69679-ref77"><label>77</label><mixed-citation publication-type="other" xlink:type="simple">Uppal, B., Berry, N., Kahar, S. and Ramji, S. (1999) Vibrio cholera O1 Serotype Ogawa in Neonate. Diagnostic Microbiology and Infectious Disease, 33, 63-64. http://dx.doi.org/10.1016/S0732-8893(98)00131-X</mixed-citation></ref><ref id="scirp.69679-ref78"><label>78</label><mixed-citation publication-type="book" xlink:type="simple">Elliot, E.L., Kaysner, C.A., Jackson, L. and Tamplin, M.L. (2001) Vibrio cholera, V. parahemolyticus, V. valnificus and other Vibrio spp. In: Merker, R.L., Ed., Food and Drug Administration: Bacteriological Analytical Manual, 8th Edition, Chapter 9, AOAC International, Gaithersburg.</mixed-citation></ref><ref id="scirp.69679-ref79"><label>79</label><mixed-citation publication-type="other" xlink:type="simple">Faulkner, C.T., Garcia, B.B., Logan, M.H., New, J.C. and Patton, S. (2003) Prevalence of Endoparasitic Infection in Children and Its Relation with Cholera Prevention Efforts in Mexico. Revista Panamericana de Salud Pública, 14, 31-41. http://dx.doi.org/10.1590/S1020-49892003000600006</mixed-citation></ref><ref id="scirp.69679-ref80"><label>80</label><mixed-citation publication-type="other" xlink:type="simple">Slanthia, P. and Bansal, M.P. (1999) Incidence of Vibrio cholera in Different Age Groups and Sex in Aurangabad Province Isolated during January 1994 to December 1994. Indian Journal of Medical Sciences, 53, 349-351.</mixed-citation></ref><ref id="scirp.69679-ref81"><label>81</label><mixed-citation publication-type="other" xlink:type="simple">Qureshi, K., Molbak, K., Sadstrom, A. and Kofoed, P. (2006) Breast Milk Reduces the Risk of Illness in chiLdren of Mothers with Cholera: Observation from an Epidemic of Cholera in Guinea-Bissau. Pediatric Infectious Disease Journal, 25, 1163-1166. http://dx.doi.org/10.1097/01.inf.0000246977.58697.a5</mixed-citation></ref><ref id="scirp.69679-ref82"><label>82</label><mixed-citation publication-type="other" xlink:type="simple">Ali, M., Nelson, A.R., Lopez, A.L. and Sack, D.A. (2015) Updated Global Burden of Cholera in Endemic Countries. PLoS Neglected Tropical Diseases, 9, e0003832. http://dx.doi.org/10.1371/journal.pntd.0003832</mixed-citation></ref><ref id="scirp.69679-ref83"><label>83</label><mixed-citation publication-type="other" xlink:type="simple">Dempouo Djomassi, L., Gessner, B.D. and Etoundi Mballa, G.A. (2013) National Surveillance Data on the Epidemiology of Cholera in Cameroon. The Journal of Infectious Disease, 208, S92-S97. http://dx.doi.org/10.1093/infdis/jit197</mixed-citation></ref><ref id="scirp.69679-ref84"><label>84</label><mixed-citation publication-type="other" xlink:type="simple">DOVE (Delivering Oral Cholera Vaccine Project) (2015) Cholera Surveillance: Detecting and Reporting Cases. Updated September 9: 1-6 Johns Hopkins Bloomberg School of Public Health 615 N. Wolfe Street/E5537, Baltimore, MD 21205, USA. https://www.stopcholera.org/.../cholera/.../stop_cholera</mixed-citation></ref><ref id="scirp.69679-ref85"><label>85</label><mixed-citation publication-type="other" xlink:type="simple">Blacklock, A., Sesay, A., Kamara, A., Kamara, M. and Blacklock, C. (2015) Characteristics and Clinical Management of Patients Admitted to Cholera Wards in a Regional Referral Hospital during the 2012 Epidemic in Sierra Leone. Global Health Action, 8, 25266. http://dx.doi.org/10.3402/gha.v8.25266</mixed-citation></ref><ref id="scirp.69679-ref86"><label>86</label><mixed-citation publication-type="other" xlink:type="simple">Yadava, J.P., Jain, M. and Goel, A.K. (2013) Detection and Confirmation of Toxigenic Vibrio cholera O1 in Environmental and Clinical Samples by a Direct Cell Multiplex PCR. Water SA, 39, 611-614. 
http://dx.doi.org/10.4314/wsa.v39i5.4</mixed-citation></ref><ref id="scirp.69679-ref87"><label>87</label><mixed-citation publication-type="other" xlink:type="simple">Ramazanzadeh, R., Rouhi, S., Shakib, P., Shahbazi, B., Bidarpour, F. and Karimi, M. (2015) Molecular Characterization of Vibrio cholera Isolated from Clinical Samples in Kurdistan Province, Iran. Jundishapur Journal of Microbiology, 8, e18119. http://dx.doi.org/10.5812/jjm.8(5)2015.18119</mixed-citation></ref><ref id="scirp.69679-ref88"><label>88</label><mixed-citation publication-type="other" xlink:type="simple">Ratna, P.V.J., Sandjarara, T. and Rajkumar, S. (2015) Genotyping of Vibrio cholera Strains Based on the Cholera Toxin and Virulence Associated Genes. Indian Journal of Applied Research, 5, 197-198.</mixed-citation></ref><ref id="scirp.69679-ref89"><label>89</label><mixed-citation publication-type="other" xlink:type="simple">Jain, M., Kumar, P. and Goel, A.K. (2016) Emergence of Tetracycline Resistant Vibrio cholera O1 Biotype El Tor Serotype Ogawa with Classical ctxB Gene from a Cholera Outbreak in Odisha, Eastern India. Journal of Pathogens, 2016, Article ID: 1695410. http://dx.doi.org/10.1155/2016/1695410</mixed-citation></ref><ref id="scirp.69679-ref90"><label>90</label><mixed-citation publication-type="other" xlink:type="simple">Matson, J.S., Withey, J.H. and Dirita, V.J. (2007) Regulatory Networks Controlling Vibrio cholera Virulence Gene Expression. Infection and Immunity, 75, 5542-5549. http://dx.doi.org/10.1128/IAI.01094-07</mixed-citation></ref><ref id="scirp.69679-ref91"><label>91</label><mixed-citation publication-type="other" xlink:type="simple">Goel, A.K., Jain, M., Kumar, P. and Jiang, S.C. (2010) Molecular Characterization of Vibrio cholera Outbreak Strains with Altered El Tor Biotype from Southern India. World Journal of Microbiology and Biotechnology, 26, 281-287. 
http://dx.doi.org/10.1007/s11274-009-0171-7</mixed-citation></ref><ref id="scirp.69679-ref92"><label>92</label><mixed-citation publication-type="other" xlink:type="simple">Bielawska-Drozd, A., Mirski, T., Bartoszcze, M., Cieslik, P., Roszkowiak, A. and Michalski, A. (2012) Development of Real-Time PCR Assay for Detection of Vibrio cholera. Polish Journal of Environmental Studies, 21, 279-288.</mixed-citation></ref><ref id="scirp.69679-ref93"><label>93</label><mixed-citation publication-type="other" xlink:type="simple">Tirapattanun, A., Chomvarin, C., Wongboot, W. and Kanoktippornchai, B. (2015) Application of SYBR Green Real-Time PCR for Detection of Toxigenic Vibrio cholera O1 in the Aquatic Environment. Chiang Mai Journal of Science, 42, 588-598.</mixed-citation></ref><ref id="scirp.69679-ref94"><label>94</label><mixed-citation publication-type="other" xlink:type="simple">Bakhshi, B., Pourshafie, M.R., Navabakbar, F., Tavakoli, A., Shahcheraghi, F., Salehi, M., Faradjzadegan, Z. and Zahraei, S.M. (2008) Comparison of Distribution of Virulence Determinants in Clinical and Environmental Isolates of Vibrio cholera. Iranian Biomedical Journal, 12, 159-165.</mixed-citation></ref><ref id="scirp.69679-ref95"><label>95</label><mixed-citation publication-type="other" xlink:type="simple">Mukherjee, M., Kakarla, P., Kumar, S., Gonzalez, E., Floyd, J.T., Inupakutika, M., Devireddy, A.R., Tirrell, S.R., Bruns, M., He, G., Lindquist, I.E., Sundararajan, A., Schilkey, F.D., Mudge, J. and Varela, M.F. (2014) Comparative Genome Analysis of Non-Toxigenic Non-O1 versus Toxigenic O1 Vibrio cholera. Genomics Discovery, 2, 1-15. 
http://dx.doi.org/10.7243/2052-7993-2-1</mixed-citation></ref><ref id="scirp.69679-ref96"><label>96</label><mixed-citation publication-type="other" xlink:type="simple">Stonehouse, E., Kovacikova, G., Taylor, R.K. and Skorupski, K. (2008) Integration Host Factor Positively Regulates Virulence Gene Expression in Vibrio cholera. Bacteriology, 190, 4736-4748. http://dx.doi.org/10.1128/JB.00089-08</mixed-citation></ref><ref id="scirp.69679-ref97"><label>97</label><mixed-citation publication-type="other" xlink:type="simple">Anvari, S., Najar, P.S., Behmanesh, M. and Boustanshenas, M. (2012) Biological Activity of Recombinant Accessory Cholera Enterotoxin (Ace) on Rabbit Illeal Loops and Antibacterial Assay. Cell Journal, 14, 209-214.</mixed-citation></ref><ref id="scirp.69679-ref98"><label>98</label><mixed-citation publication-type="other" xlink:type="simple">Al-Obidi, I.M. (2005) Determination of Some Epidemiological Markers in Locally Isolated Vibrio cholera. MSc Thesis, College of Science, University of AL-Mustansiryah, AL-Mustansiryah.</mixed-citation></ref><ref id="scirp.69679-ref99"><label>99</label><mixed-citation publication-type="other" xlink:type="simple">Duval, P., Chametier, R.G., Ranjalahy, J., Quilici, M.L. and Fournier, J.M. (1999) Cholera in Madagascar. Lancet, 353, 2068. http://dx.doi.org/10.1016/S0140-6736(99)00103-8</mixed-citation></ref><ref id="scirp.69679-ref100"><label>100</label><mixed-citation publication-type="other" xlink:type="simple">Hochhut, B., Lotfi, Y., Mazel, D., Faruque, S.M., Woodgate, R. and Waldor, M.K. (2001) Molecular Analysis of Antibiotic Resistance Gene Clusters in Vibrio cholera O139 and O1 SXT Constins. Antimicrobal Agents Chemotherapy, 45, 2991-3000. http://dx.doi.org/10.1128/AAC.45.11.2991-3000.2001</mixed-citation></ref><ref id="scirp.69679-ref101"><label>101</label><mixed-citation publication-type="other" xlink:type="simple">Sjolund-Karlsson, M., Reimer, A., Folster, J.P., Walker, M., Dahourou, G.A., Batra, D.G., Martin, R., Joyce, K., Parsons, M.B., Boncy, J., Whichard, J.M. and Gilmour, M.W. (2011) Drug Resistance Mechanisms in Vibrio cholera O1 Outbreak Strain, Haiti, 2010. Emerging Infectious Disease, 17, 2151-2154.  
http://dx.doi.org/10.3201/eid1711.110720</mixed-citation></ref><ref id="scirp.69679-ref102"><label>102</label><mixed-citation publication-type="other" xlink:type="simple">Replogle, M.L., Fleming, D.W. and Cieslak, P.R. (2000) Emergence of Antimicrobial-Resistant Shigellosis in Oregon. Clinical Infectious Diseases, 30, 515-519. http://cid.oxfordjournals.org/content/30/3/515.long   
http://dx.doi.org/10.1086/313715</mixed-citation></ref><ref id="scirp.69679-ref103"><label>103</label><mixed-citation publication-type="other" xlink:type="simple">Reller, M.E., Nelson, J.M., Molbak, K., Ackman, D.M., Schoonmaker-Bopp, D.J., Root, T.P. and Mintz, E.D. (2006) A Large, Multiple-Restaurant Outbreak of Infection with Shigella flexneri Serotype 2a Traced to Tomatoes. Clinical Infectious Diseases, 42, 163-169. http://cid.oxfordjournals.org/content/42/2/163.long  
http://dx.doi.org/10.1086/498900</mixed-citation></ref><ref id="scirp.69679-ref104"><label>104</label><mixed-citation publication-type="other" xlink:type="simple">APHA (American Public Health Association) (2008) Shigellosis, in Control of Communicable Diseases Manual, Edited by Heymann, D.L., Presented by Clark, M., 19th Edition, 556-560.  
http://www.about-shigella.com/shigella_references</mixed-citation></ref><ref id="scirp.69679-ref105"><label>105</label><mixed-citation publication-type="other" xlink:type="simple">Su, L.H., Chiu, C.H., Chu, C. and Ou, J.T. (2004) Antimicrobial Resistance in Non Typhoid Salmonella Serovars: A Global Challenge. Clinical Infectious Diseases, 39, 546-451. http://dx.doi.org/10.1086/422726</mixed-citation></ref><ref id="scirp.69679-ref106"><label>106</label><mixed-citation publication-type="other" xlink:type="simple">Mijovic, G., Andric, B., Terzic, D., Lopicic, M. and Dupanovic, B. (2012) Antibiotic Susceptibility of Salmonella spp.: A Comparison of Two Surveys with a 5 Years Interval. Journal of IMAB, 18, 216-219. 
http://dx.doi.org/10.5272/jimab.2012181.216</mixed-citation></ref></ref-list></back></article>